|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||47.32 - 47.88|
|52 Week Range||38.01 - 57.83|
|Beta (3Y Monthly)||0.72|
|PE Ratio (TTM)||33.22|
|Earnings Date||Feb 21, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||56.45|
Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Globus Medical Inc NYSE:GMEDView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for GMED with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting GMED. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding GMED totaled $914 million. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
AUDUBON, Pa., Feb. 05, 2019 -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and.
NEW YORK, Jan. 30, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
A long term, seven-year clinical trial follow-up study published in the prominent International Journal of Spine Surgery demonstrated the superiority of SECURE-C® in terms of overall success, compared to Anterior Cervical Discectomy and Fusion (ACDF), the current standard of care for cervical disc disease. The SECURE-C® Cervical Artificial Disc is implanted using an anterior approach.
By now, investors have had plenty of time to evaluate the performance of their portfolios in 2018. Chances are good that most investors who have done this didn't enjoy the trip down memory lane. That's because 2018 was a tough year to pick stocks to buy. In fact, it was the worst year for stocks in the past decade and the worst December since 1931. And boy was the final month of the year volatile with stocks up or down by more than 1% on nine occasions. Throughout 2018, stocks were up or down by 1% on 64 occasions, eight times more often than in 2017. Investors forgot that stocks don't go up in a straight line; that volatility was more than just something that happened to gas prices. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Once upon a time, volatility was considered a good thing when it came to the markets because it shook out all the weak hands giving investors a more accurate picture of what a stock was worth and where it was headed. It's time for investors to come to grips with the fact volatility in the markets has returned, most likely permanently. And it's far better to figure out a strategy that works in this kind of environment than for investors to bury their heads in the sand. One way to do so is to find stocks to buy that have lost a significant amount over the past 30 days. With volatility back in the game, many of these stocks could just as easily bounce back by as much or more in the months ahead. * 10 Consumer Stocks to Buy for Income Here are seven stocks that have declined by 20% or more over the past 30 days that I believe could bounce back over the next 30-60 days. ### Albemarle (ALB) Source: fdecomite via Flickr (Modified) 3-Month Performance: -20% Relative to S&P 500: -17% As recently as early November, CNBC's Mad Money host Jim Cramer liked Albemarle (NYSE:ALB) -- the specialty chemicals company that provides lithium, bromine and refining catalysts to companies who use them in the manufacturing processes of their end-use products. "It had good numbers. It's straight up. I still like it here. The numbers were terrific, " Cramer stated Nov. 7 on Mad Money. "Some people didn't like the sales numbers; give me a break." Since then, ALB stock has lost 30% of its value. Albermarle reports fourth-quarter results Feb. 20 after the markets close. In the third quarter, as Cramer alluded to, Albermarle grew its revenue by 3% year-over-year to $129.7 million with earnings-per-share of $1.20, 13% higher than a year earlier. The 3% sales growth might not have been enough for investors, but looking on the bright side, it was the company's 11th consecutive quarter increasing revenue. As Cramer stated, there's nothing wrong with those numbers. For the entire year, Albermarle expects revenue growth and adjusted EPS growth of at least 7% and 15%, respectively, for all of 2018 when it reports the fourth-quarter results in a month. I expect the stock to react positively to the news. ### Apple (AAPL) Source: Shutterstock 3-Month Performance: -27% Relative to S&P 500: -24% First, it was iPhone sales in China that got Apple (NASDAQ:AAPL) followers nervous about the company's future and now it appears the latest worry to add to the wall of worry is its services revenues. "While the services segment grew 18 percent in the December quarter, we've now started to get investor questions worrying about whether the App Store will be the next shoe to drop," AB Bernstein's Toni Sacconaghi wrote in a note Jan. 18. "Certainly, the headlines in the last few months haven't been encouraging. Netflix, Spotify, and Fortnite have all stopped / threatened to stop paying the so-called 'Apple Tax' of 15 to 30 percent on App Store revenues." Throw that on the pile of concerns investors have about AAPL stock at the moment. One thing I know for sure: Just as Warren Buffett bought a bunch of Apple stock in the third quarter of 2018, he likely bought more in the fourth quarter as Apple was falling, and I bet you he'll be buying more in the first quarter if it continues to drop in value. * The 10 Best Index Funds to Buy and Hold Apple's business isn't broken. Its stock is. The latter's a much better problem to have than the former. ### Constellation Brands (STZ) Source: Jirka Matousek via Flickr (Modified) 3-Month Performance: -27% Relative to S&P 500: -24% Volatility was a big deal in 2018 and nowhere was that truer than in the cannabis industry. Constellation Brands (NYSE:STZ) owns a big piece of Canopy Growth (NYSE:CGC), one of Canada's biggest cannabis companies. Earlier in January, the company cut its guidance for the full year due in part to its $4 billion investment in Canopy Growth along with weakness in its wine and spirits business. Given companies now have to account for changes in the unrealized value of equity investments every quarter, profits can vary. In the case of Constellation, it had a $164 million decrease in the fair value of its Canopy Growth investment, and that goes right against the bottom line. It's possible the same thing will happen when it reports its fourth-quarter results. Also, because of the debt taken to invest so heavily in Canopy Growth, Constellation will incur an additional $55 million in interest in fiscal 2019, an impact of 25 cents a share. Not to worry. Long term, Constellation's $4 billion investment in Canopy could turn out to be peanuts if its expectations for the cannabis industry come to pass. "[Marijuana] represents one of the most significant global growth opportunities of the next decade and frankly, our lifetimes," CEO Bill Newlands said in its Q3 2018 conference call. "It's an opportunity that is opening up much more rapidly than originally anticipated." I couldn't agree more. ### Globus Medical (GMED) Source: Shutterstock 3-Month Performance: -21% Relative to S&P 500: -18% If you suffer from spinal-related issues, you've likely heard of Globus Medical (NYSE:GMED), a Pennsylvania-based orthopedic company that manufactures a comprehensive portfolio of innovative products to help surgeons and doctors provide patients with the appropriate treatment options. Since its founding in 2003, it has launched more than 190 products that it sells through its own sales force as well as through distributors and third-party sales reps. When the company announced Q3 2018 results in November, which saw weaker revenues than expected, investors punished its stock. However, it looks as though that might have been an overreaction. In early January, Needham analyst Michael Matson had some very positive things to say to his clients. "After the close on 1/8/19, GMED preannounced 4Q18 revenue that was above consensus. GMED also provided initial 2019 revenue guidance that was above consensus and non-GAAP EPS guidance that was a penny below consensus," Matson wrote. "We believe the 2019 revenue guidance could prove conservative given continued growth in robot unit sales, increasing robotics implant pull-through, and the trauma implant launch and we reiterate our Buy rating." Now, to be sure, one analyst does not make an omelet. However, of the ten analysts that cover GMED stock, only one has an underperform or sell rating at the moment. * 7 Stupidly Cheap Stocks to Buy Now Buy on weakness. ### Stocks to Buy: Nvidia (NVDA) Source: Shutterstock 3-Month Performance: -34% Relative to S&P 500: -31% While 2018 is a year most Nvidia (NASDAQ:NVDA) shareholders would like to put behind them -- it lost 39% of its value as many of the big semiconductor stocks got hit -- there's a lot to look forward to in 2019. Year-to-date, NVDA stock is up 18% through Jan. 18, in part because of the new GoForce RTX 2060 gaming GPU that uses Turing architecture and is priced at $349, allowing gamers using laptops relatively inexpensive access to the new technology. Will a cheaper version of its RTX GPUs be enough to offset the reduced demand of its products from cryptocurrency miners? Probably not, but good news definitely can't hurt. I've been a fan of NVDA stock for some time; 2018 was a tough year for those recommending its shares. On a positive note, well-known finance professor Aswath Damodaran bought Nvidia shares in December at $145. While it dropped below his purchase price, he's confident it's an excellent long-term play. "I'm still waiting to get back to $145. I might never get there, but I like the company," Damoradan said Jan. 9 on CNBC. "I mean, I think that there is a real chance growth can drop off next year, but I think long term I would still buy the growth in that stock at the prices that you get them for today." Nvidia is a growth stock dressed up in a value stock's clothing. ### Grand Canyon Education (LOPE) Source: Shutterstock 3-Month Performance: -22% Relative to S&P 500: -19% A lot of people don't like Jim Cramer's schtick. I'm not one of his detractors. As I've said before on InvestorPlace, we all get things wrong sometimes when recommending stocks. He talks about so many different companies, so it's easy to understand why he gets some calls wrong. However, in October, Cramer got Grand Canyon Education (NASDAQ:LOPE) 100% right. "The for-profit education industry tends to thrive under Republican presidents, as Democrats tend to view the whole business as something that's predatory," Cramer said Oct. 1. "I think you can put on a small speculative position in Grand Canyon here, but wait until after the election to buy more because the stock might sell off if the Democrats take Congress." Well, Americans headed to the polls Nov. 6, and the Democrats indeed took back the House, if not the entire Congress. Since then, LOPE stock is down 26%. * 3 Blue-Chip Stocks That Will Power Through Market Turmoil It has been a long time since I've recommended an education stock, but given its annual revenue and cash flows are both at record levels, and it's trading for 25% less than it did three months ago, I'd say it's a good bet for 2019. ### Stocks to Buy: SVB Financial (SIVB) Source: Shutterstock 3-Month Performance: -20.0% Relative to S&P 500: -17% 2018 was one of those rare years where SVB Financial (NASDAQ:SIVB) stock didn't do right by shareholders with a loss 19% on the year. This was its first year in negative territory since 2011. "Don't worry", I thought to myself as the year came to a close. SIVB would rebound in 2019. Indeed it has, up 22% YTD through Jan. 21. Here's what I said about SVB Financial on the last day of 2018: "Since SVB, America's most innovative bank, has lost 39% of its value over the past three months and trades within 8% of its 52-week low, I'll vote for it as the best bank stock to own in 2019." With a healthy net interest margin expected for fiscal 2018 of at least 3.55%, 94 basis points higher than Bank of America (NYSE:BAC), and possessing an east coast presence in the healthcare industry through its $340 million acquisition of Boston-based Leerink Holdings LLC, I see 2019 as a year where it delivers on its long-term, 10-year annualized total return of 26%. Happy Banking. As of this writing, Will Ashworth did not hold a position in any of the aforementioned securities. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Consumer Stocks to Buy for Income * 7 Dark Horse Stocks You Really Need to Look at for 2019 * 7 Retail Stocks to Buy for the Rise of Menswear Compare Brokers The post 7 Stocks to Buy That Lost 20% Over Past 90 Days appeared first on InvestorPlace.
Globus Medical, Inc. (NYSE:GMED) is a stock with outstanding fundamental characteristics. When we build an investment case, we need to look at the stock with a holistic perspective. In the Read More...
On January 9, Globus Medical (GMED) was trading at a stock price of $43.79, which is an ~9.91% rise from its closing price of $39.84 on January 8. On January 4, Globus Medical’s stock price rose ~5.04% to $40.00 from its close of $38.08 on January 3. On January 3, the company hit its 52-week low of $38.01.
HOUSTON, TX / ACCESSWIRE / January 9, 2019 / Technology has changed in the blink of an eye. Concepts that were nothing more than science fiction, such as artificial intelligence (AI) and machine learning are now quickly disrupting global industries with significant capabilities. In fact, the limitless potential of AI alone is disrupting businesses, the way we conduct our affairs, and even the way financial institutions conduct high-frequency trading.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech Stocks Hitting 52-week highs on Jan. 8) Innoviva Inc (NASDAQ: INVA ) Organogenesis Holdings Inc ...
Globus Medical, Inc. (GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ending December 31, 2018. The company anticipates fourth quarter 2018 sales of approximately $195.5 million, an increase of 11.0% over the fourth quarter 2017. “Our fourth quarter and full year results are indicative of strong momentum in several key strategic areas,” said Dave Demski, CEO.
Mid-caps stocks, like Globus Medical, Inc. (NYSE:GMED) with a market capitalization of US$4.4b, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-cap Read More...
Hedge funds are not perfect. They have their bad picks just like everyone else. Facebook, a stock hedge funds have loved, lost a third of its value since the end of July. Although hedge funds are not perfect, their consensus picks do deliver solid returns, however. Our data show the top 30 S&P 500 stocks […]
NEW YORK, NY / ACCESSWIRE / December 7, 2018 / U.S. equities finished modestly lower on Thursday as trade concerns were reignited after the arrest of a Huawei senior executive. The Dow Jones Industrial ...
Globus Medical, Inc. (GMED), a leading musculoskeletal solutions company, recently announced the entrance of ExcelsiusGPS®, a revolutionary robotic guidance and navigation system, to the international market with system installations completed in several European countries. This past October, the first European Excelsius GPS® procedure was performed at the Metropolitan Hospital in Neo Faliro, Athens, Greece by Mr. Panagiotis E. Zoumpoulis. Since then, numerous open and minimally invasive spine procedures have been performed at Bonifatius Hospital in Germany and at the Fornaca Clinic in Italy.
Surgical robots are increasingly being placed in hospital operating rooms. AlphaCentric Global Innovation's portfolio manager names a few investment opportunities in this fast-growing space.
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.